(1) Unfortunately, for both entecavir (ETV) and tenofovir disoproxil fumarate (TDF), HBeAg clearance or seroconversion only occurs in a minority of patients even after multiple years of antiviral therapy. The gut microbiota appears to play a critical role in age-related immune clearance of HBV. (2) Several studies have indicated that CHB patients with liver cirrhosis have different microbiota compared to healthy people. (3, 4) The "leakage hypothesis" has linked gut microbiota to the onset and progression of liver diseases.
(5) Thus, we reported on a case-controlled, open-label pilot trial of fecal microbiota transplantation (FMT) for CHB patients.
Methods and Results
In the present study, 18 eligible patients who remained persistently positive for HBeAg following >3 years of ongoing ETV-or TDF-based antiviral therapy were enrolled (Table 1) . Among them, 5 participants were enrolled in the FMT arm whereas 13 were enrolled in the control arm according to whether they accepted FMT or not. All participants in both arms continued with their previous antiviral treatment such as ETV. After obtaining written informed consents, FMT treatment was performed by gastroscope for the participants in the FMT arm every 4 weeks until HBeAg clearance was achieved. Four of 5 patients in the trial arm received one to seven FMT treatments, and 1 participant exited the trial after five FMT treatments. The FMT treatment schedule and donor information for each patient are outlined in Supporting Fig. S1A . Gut microbiota profiling was performed for all donors and patients in the FMT arm, which indicated there was a significant change in the microbiota composition compared to that at the baseline (Fig. 1A) . Principal components analysis showed that the gut microbiota profile of the donors was distinct from that of the participants in the FMT arm at baseline (Supporting Fig. S1B ).
At the end of follow-up, a significant decline in HBeAg titer rather than hepatitis B surface antigen (HBsAg) titer was observed in the FMT arm compared to that at the baseline (Fig. 1B and Supporting Fig.   S1C ). Moreover, HBeAg titer declined gradually after each round of FMT (Supporting Fig. S1D ). In the FMT arm, 2 participants (patients C and E) achieved HBeAg clearance after one FMT whereas patient D achieved HBeAg clearance after two FMT treatments. In contrast to that, none of the control patients achieved HBeAg clearance (0 of 13) at the conclusion of the study (P 5 0.0001, Mantel-Cox's test; Fig. 1C ). Alanine aminotransferase (ALT) and HBV DNA were also detected at 4 weeks after each round of FMT and remained under the lower limit of detection (data not shown). No HBeAg seroconversion was observed at the end of follow-up. No significant adverse events, such as 
Discussion
We report on this trial of FMT for the treatment of HBeAg-positive CHB in patients with ongoing ETV/ TDF therapy. The results demonstrated that FMT can induce HBeAg clearance in a significant proportion of the cases who have persistent positive HBeAg even after long-term antiviral treatment. This result was especially encouraging for patients with HBeAg-positive CHB who otherwise could not cease oral antiviral treatment. Although only 5 patients were enrolled in the FMT arm, robust statistical differences (P 5 0.0001; Fig. 1C ) and dramatic outcomes were observed. Enrollment of suitable participants is typically challenging without pilot trials demonstrating promising outcomes. In conclusion, this study demonstrated the efficacy of FMT on HBeAg-positive CHB, especially in patients who could not otherwise cease the oral antiviral treatment even after long-term treatment. This trial provided evidence that suggests the benefit of modulating gut microbiota for CHB treatment. However, a larger trial is needed in the future.
